These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 17192459)

  • 21. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.
    Lykkegaard K; Larsen PJ; Vrang N; Bock C; Bock T; Knudsen LB
    Schizophr Res; 2008 Aug; 103(1-3):94-103. PubMed ID: 18579346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats.
    Akarte AS; Srinivasan BP; Gandhi S; Sole S
    Eur J Pharm Sci; 2012 Sep; 47(2):456-63. PubMed ID: 22800967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
    Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
    Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
    Ahrén B
    Curr Diab Rep; 2007 Oct; 7(5):340-7. PubMed ID: 18173966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.
    Burkey BF; Li X; Bolognese L; Balkan B; Mone M; Russell M; Hughes TE; Wang PR
    J Pharmacol Exp Ther; 2005 Nov; 315(2):688-95. PubMed ID: 16027230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.
    Sa-Nguanmoo P; Tanajak P; Kerdphoo S; Jaiwongkam T; Pratchayasakul W; Chattipakorn N; Chattipakorn SC
    Toxicol Appl Pharmacol; 2017 Oct; 333():43-50. PubMed ID: 28807765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats.
    Zhang Q; Xiao X; Li M; Yu M; Ping F; Zheng J; Wang T; Wang X
    PLoS One; 2017; 12(10):e0184735. PubMed ID: 29036231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
    Yamaguchi M; Saji T; Mita S; Kulmatycki K; He YL; Furihata K; Sekiguchi K
    Int J Clin Pharmacol Ther; 2013 Aug; 51(8):641-51. PubMed ID: 23782587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
    Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats.
    Herling AW; Kilp S; Elvert R; Haschke G; Kramer W
    Endocrinology; 2008 May; 149(5):2557-66. PubMed ID: 18276749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
    Horowitz M; Flint A; Jones KL; Hindsberger C; Rasmussen MF; Kapitza C; Doran S; Jax T; Zdravkovic M; Chapman IM
    Diabetes Res Clin Pract; 2012 Aug; 97(2):258-66. PubMed ID: 22446097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.
    Silver HJ; Olson D; Mayfield D; Wright P; Nian H; Mashayekhi M; Koethe JR; Niswender KD; Luther JM; Brown NJ
    Diabetes Obes Metab; 2023 Aug; 25(8):2340-2350. PubMed ID: 37188932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estrogen and DPP4 inhibitor, but not metformin, exert cardioprotection via attenuating cardiac mitochondrial dysfunction in obese insulin-resistant and estrogen-deprived female rats.
    Sivasinprasasn S; Sa-Nguanmoo P; Pongkan W; Pratchayasakul W; Chattipakorn SC; Chattipakorn N
    Menopause; 2016 Aug; 23(8):894-902. PubMed ID: 27326818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liraglutide suppression of caloric intake competes with the intake-promoting effects of a palatable cafeteria diet, but does not impact food or macronutrient selection.
    Hyde KM; Blonde GD; le Roux CW; Spector AC
    Physiol Behav; 2017 Aug; 177():4-12. PubMed ID: 28366815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
    Ahrén B; Schweizer A; Dejager S; Villhauer EB; Dunning BE; Foley JE
    Diabetes Obes Metab; 2011 Sep; 13(9):775-83. PubMed ID: 21507182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4.
    Jessen L; Aulinger BA; Hassel JL; Roy KJ; Smith EP; Greer TM; Woods SC; Seeley RJ; D'Alessio DA
    Endocrinology; 2012 Dec; 153(12):5735-45. PubMed ID: 23033273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice.
    Shimizu S; Hosooka T; Matsuda T; Asahara S; Koyanagi-Kimura M; Kanno A; Bartolome A; Etoh H; Fuchita M; Teruyama K; Takahashi H; Inoue H; Mieda Y; Hashimoto N; Seino S; Kido Y
    J Mol Endocrinol; 2012 Oct; 49(2):125-35. PubMed ID: 22822047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-obesity effects of KR-66195, a synthetic DPP-IV inhibitor, in diet-induced obese mice and obese-diabetic ob/ob mice.
    Lee EY; Kim YW; Oh H; Choi CS; Ahn JH; Lee BW; Kang ES; Cha BS; Lee HC
    Metabolism; 2014 Jun; 63(6):793-9. PubMed ID: 24684824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.
    El-Ouaghlidi A; Rehring E; Holst JJ; Schweizer A; Foley J; Holmes D; Nauck MA
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4165-71. PubMed ID: 17698900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.